

Lidocaine Topical Solution Recall Alert

Date of Notice: 12/07/2021

Brief Description of Recall Alert

Buena, NJ, Teligent Pharma, Inc. is voluntarily recalling two lots of Lidocaine HCl Topical Solution USP 4%, 50ml in a screw cap glass bottle listed in the table below to the user level. The product is being recalled because the firms testing has found it to be super potent based on an Out of Specification (OOS) result obtained at the 9-month (Lot 16345) and 18-month (Lot 15594) stability timepoint.

Risk Statement: Use of the super potent product would result in a higher than intended lidocaine dose above that intended. An increased lidocaine dose could lead to the development of local anesthetic systemic toxicity depending on the duration of the treatment and the specific patient. Local anesthetic systemic toxicity can result in central nervous system reactions including excitation and/or depression and more serious signs of cardiovascular toxicity, such as bradycardia, hypotension, and even cardiovascular collapse can present very quickly. If local anesthetic systemic toxicity is not recognized and treated quickly, severe morbidity and even death can result. Adults and the elderly who are more likely to use this product as well as children of lower body weight are more likely to experience local anesthetic systemic toxicity if a higher than intended lidocaine concentration is administered.

Affected Products

Drug Name & Strength	NDC	Lot	Expiration Date
Lidocaine Hydrochloride Topical Solution USP 4% (40 mg/mL), 50mL bottle	63739-997-64	15594 16345	05/2023 01/2024

Prescriber Information

Teligent Pharma, Inc. is notifying its distributors via Fed-Ex and is arranging for return of all recalled products. Consumers, distributors, and retailers that have product which is being recalled should stop using or distributing and return to place of purchase.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

- Complete and submit the report <u>Online</u>
- Regular Mail or Fax: <u>Download form</u> or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

Member Information

Consumers and patients that have Lidocaine HCl Topical Solution 4% which is being recalled are asked to discontinue use and call 1-856.697.1441 press * to reach the medical information call center Monday

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.

© 2020 RxAdvance Corporation. Confidential and Proprietary.

Page 1 of 2 v 2.7.04.1



through Friday, 8am – 5pm or send an e-mail to Medical@teligent.com for any product questions and to receive instructions on reimbursement and shipping info for Lot #15594 Exp. 05/2023 and Lot #16345 Exp. 01/2024.

RxAdvance Response

Members should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.

© 2020 RxAdvance Corporation. Confidential and Proprietary.

Page 2 of 2 v 2.7.04.1